All type of patients: 25 trials - SAVOR-TIMI 53 - Fonseca - Kawamori - Forst - Nowicki - Nowicki - Yang - Göke - Scheen - Stenlöf - DeFronzo - Jadzinsky - Rosenstock - CV181-011 - CV181-038 - CV181-040 - CV181-041 - CV181-057 - CV181-066 - CV181-080 - CV181-085 - Hollander - saxagliptin - saxagliptin vs sitagliptin - saxgliptin, renal study
All types of patients: 25 trials - SAVOR-TIMI 53 - Fonseca - Kawamori - Forst - Nowicki - Nowicki - Yang - Göke - Scheen - Stenlöf - DeFronzo - Jadzinsky - Rosenstock - CV181-011 - CV181-038 - CV181-040 - CV181-041 - CV181-057 - CV181-066 - CV181-080 - CV181-085 - Hollander - saxagliptin - saxagliptin vs sitagliptin - saxgliptin, renal study
Drug naïve patients: 4 trials - Rosenstock - CV181-011 - CV181-038 - CV181-041
In patients inadequately controlled on standard therapy: 1 trials - saxgliptin, renal study
Patients inadequately controlled on metformin: 3 trials - DeFronzo - CV181-080 - saxagliptin vs sitagliptin
Patients inadequately controlled on monotherapy : 6 trials - DeFronzo - Jadzinsky - CV181-066 - CV181-080 - Hollander - saxagliptin vs sitagliptin
Patients inadequately controlled on TZD: 1 trials - Hollander
Patients inadequately controlled with insulin: 1 trials - CV181-057
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
